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Background. Reports by hepatologists indicated that anti-HCV antibodies might be
detected in 71% to 84% of cases of post-transfusion hepatitis and in up to 50% of
cases of sporadic non-A non-B hepatitis. Anti-HCV antibodies were detected in
0.05−1% of blood donors with normal alanine transaminase (ALT) levels and negative
anti-HBc screening. Anti-HCV antibodies were found in 67% of patients with a history
of intravenous drug abuse or autoimmune hepatitis, and in 10−30% of patients with
hepatocellular carcinoma. This indicated that hepatitis C virus was a major cause of
the acute and chronic hepatitis throughout the world. Methods. This was a multicen-
teric, international, double-blind, randomized, placebo-controlled study. After the
eight-week screening period, patients were randomized to receive daily ribavirin 1200
mg or placebo, during the 48-week treatment period. Follow-up observations were
performed during a 16 week post-treatment period. Up to 80 male and female outpa-
tients with mild to moderate chronic active hepatitis C virus infection were enrolled in
this study. Results. During the treatment period ALT values were significantly lower in
the ribavirin group. Neither in the ribavirin group, nor in the placebo group signifi-
cant statistical differences of the HCV RNA values were found. Significantly lower
portal inflammation was noticed in ribavirin group after the treatment. Analysis of
laboratory data demonstrated that ribavirin therapy was associated with mild to mod-
erate reversible anemia.  Investigator’s evaluation of the effect of the therapy on pa-
tient’s well being showed statistically significant differences in the benefit of the riba-
virin group. Conclusion. In this study ribavirin was more effective than placebo in re-
ducing ALT levels during the treatment period of the applied therapy in patients with
chronic active hepatitis C.
K e y   w o r d s :   hepatitis C, chronic; ribavirin; alanine transaminase;
blood cell count; hematocrit; hepacivirus.
Introduction
The explosion of data on the frequency of hepatitis C
indicate that anti HCV (anti C 100-3) might be detected in
71−84% of cases of post-transfusion hepatitis and in up to
50% of cases of sporadic non-A non-B hepatitis.
Anti-HCV was detected in 0.05−1% of blood donors
with normal alanine transaminase (ALT) levels and nega-
tive anti-HBc screening (1−4, 8).  Anti-HCV was found in
up to 67% of patients with a history of intravenous drug
abuse or autoimmune hepatitis, and in 10−30% of patients
with hepatocellular carcinoma (6, 7). This indicated that
hepatitis C virus was a major cause of the acute and chronic
hepatitis throughout the world (5).
Although the data were incomplete, in most patients
hepatitis C appeared to be related to parenteral inoculation,Страна 480 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 5
particularly in those with the history of iv drug abuse. The
interval between the transfusion and seroconversion was
about 22 weeks (range 10 to 39 weeks). After the presenta-
tion with hepatitis, the mean interval to seroconversion was
15 weeks (range 4 to 32 weeks) (8). Transmission of the
disease to household contacts or to sexual partners was
probably minimal (9).
Acute hepatitis C is usually mild and the patient is of-
ten anicteric (10). Clinically, the disease is indistinguishable
from other forms of viral hepatitis. The histologic picture is
non-specific, with portal inflammation, variable degrees of
parenchymal necrosis and active cirrhosis in severe cases.
The most significant feature of hepatitis C is the fre-
quency of chronic liver disease development in patients.
Even mild cases tend to progress insidiously over time, of-
ten resulting in cirrhosis. Age may be a risk factor, with
older patients developing more histologic abnormalities.
The main antiviral agents studied in the treatment of
chronic hepatitis C patients were acyclovir and interferon.
However, controlled studies with these drugs failed to dem-
onstrate their efficacy in this indication.
Ribavirin − 1-beta-D-ribofuranosyl-1,2,4-triazole-3-car-
boxamide, demonstrated efficacy when administered through
various routes (oral, aerosol and parenteral) and various for-
mulations against a variety of other viral diseases.
The mechanism of action has not been determined so
far. One of the hypotheses suggested that the treatment with
this antiviral agent resulted in the decreased intracellular
pools of guanosine triphosphate, thereby indirectly sup-
pressing synthesis of viral nucleic acid. Another hypothesis
suggested that the treatment of viral-infected cells with ri-
bavirin resulted in the synthesis of RNA with abnormal
5’cap structures, which, in turn, led to inefficient translation
of viral transcripts. It was difficult to determine experimen-
tally the primary mechanism of action because none of the
hypotheses were mutually exclusive.
An important characteristic of ribavirin is its rapid ab-
sorption with bioavailability ranging from nearly 100% in
some animal models to 33−69% in humans. Maximum plasma
concentrations of ribavirin following oral administration were
reached within 1−2 hours in human volunteers. Ribavirin
pharmacokinetics appeared to be linear over the dose range of
600−2400 mg. Ribavirin was distributed throughout the body
including the red blood cells and cerebrospinal fluid. Red
blood cells generally displayed the rapid uptake of the drug,
and ribavirin concentrations remained elevated long after the
plasma levels declined to near-zero values. Excretion was al-
most entirely via urine in the form of the unchanged drug, and
the major metabolite, 1,2,4-triazole-3-carboxamide. In subjects
with normal renal and liver function the unchanged drug was
found to have a plasma half-life, ranging between 16 and 18 h,
while in patients with the impaired renal or liver function the
half-life of ribavirin ranged between 143 and 173 h.
With long-term oral clinical administration of 600 mg
of ribavirin b.i.d., ribavirin was being accumulated in
plasma, reaching steady state within 4 weeks.
Prolonged administration of ribavirin resulted in re-
versible normocytic and normochromic anemia, due to
moderate intravascular hemolysis with an associated delay
in the late phase of erythroblast maturation.
In the hepatitis C patients, ribavirin doses of 16
mg/kg/day were with a mean decrease of less than 15% in
hemoglobin levels. This decrease was most evident from
weeks one to five, after which hemoglobin concentrations
stabilized. Within six weeks of therapy cessation hemoglo-
bin levels had normalized.
Our study was designed to evaluate the effectiveness
of a 48-week course of ribavirin therapy in subjects with
chronic active hepatitis C. This study was conducted in the
countries of Central and East European Region (Hungary,
Yugoslavia, Poland, Czech Republic and Russia), where 8
research centers participated: Szent Laszlo Hospital, Buda-
pest; Institute for Infectious and Tropical Diseases, Clinical
Center of Serbia, Belgrade; Infectious Clinic, Military
Medical Academy, Belgrade; Institute for Infectious Dis-
eases, Medical Academy, Warsaw; Charles University, In-
ternal Medicine, Prague; I Interna Klinika, Fakultetni Ne-
mocnice, Hradec Kralove; D. I. Ivanovski Institute of Vi-
rology, Moscow; Gamaleya Research Institute of Epide-
miology and Microbiology, Moscow, Russia.
This international, multicenter study was conducted by
8 principal investigators, 2 supervisors (for HCV RNA de-
tection and for histopathological detection), 15 clinical in-
vestigators and by the Sponsor’s team consisting of the pro-
fessionals experienced in clinical trials.
The objectives of this study were to evaluate the effi-
cacy and safety of oral ribavirin in up to 80 evaluable pa-
tients with mild to moderate chronic active hepatitis C virus
infection, tested in a double-blind, placebo-controlled study,
with 48-week course of therapy and with 16-week follow-
up period.
Primary efficacy assessment criterion, according to the
study protocol, was the response status based on serum
aminotransferase activity (ALT) levels and on HCV RNA
levels.
Secondary efficacy criteria included changes in liver
histopathology and changes in patient’s clinical symptoms.
Safety was to be evaluated by comparing the adverse
events, changes in laboratory values and tolerability of the
drug regimen between the ribavirin and the placebo groups.
The timepoints of primary interest for the evaluation of
efficacy were week 48 (the end of the treatment period) and
week 64 (the end of the post-treatment follow-up).
Methods
This was a multicenter, international, double-blind,
randomized, placebo-controlled study. After the eight-week
screening period, patients were randomized to receive riba-
virin 1200 mg daily, or placebo during a 48-week treatment
period. Follow-up observations were performed during a
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Up to 80 male and female outpatients with mild to
moderate chronic active hepatitis C virus infection were en-
rolled in this study. The sample size estimate was based on
the primary efficacy variable, and the percent of patients
with normalization of ALT.
Anticipating non-evaluable patients and dropouts, 40
patients per group were enrolled. To be eligible for the
study, patients were to meet the criteria outlined below:
Inclusion criteria specified that the patients should be
18−70 years of age, of both sexes, with elevated serum ami-
notransferase (ALT) activity, 1.5 times (<400 U/l) the upper
limit of normal at least 6 months prior to baseline, pro-
thrombin time less than 3 s prolonged from medium pro-
thrombin time, chiron RIBA 3-HCV test system, liver bi-
opsy consistent with chronic hepatitis, as defined by portal
inflammation with no fibrosis, or with fibrous portal expan-
sion; (Knodell Score of Periportal Activity and Lobular Ne-
crosis should be at least 1; Knodell Score for components:
periportal necrosis with or without bridging necrosis; intra-
lobular degeneration; focal necrosis and portal inflammation
should be less than 12); compensated liver disease; CD4  and
CD8 T cell within the normal range; Hematocrit ≥ 32% and
hemoglobin ≥ 10.5 g/l; serum albumin > 35g/dl; no previous
treatment with α-interferon; sexually active patients who
practiced the acceptable method of contraception and signed
the informed consent.
Exclusion criteria included: Gilbert disease; clinically
evident ascites or the history of one, endogenous hepatic
encephalopathy or bleeding esophageal varices; pregnancy;
women who could not take adequate contraceptive precau-
tion, serologic positivity for hepatitis B surface or HIV an-
tibody (confirmed by Western blotting), significant sys-
temic illnesses other than liver disease (e.g. uncontrolled
congestive heart failure, uncontrolled diabetes mellitus, he-
mophilia etc.); renal impairment, creatinine clearance below
lower limit of normal; patients having a liver biopsy with
features of other forms of liver disease; clinically significant
ECG abnormalities; oral or parenteral antiviral or immuno-
suppressive therapy within 6 months prior to the study; evi-
dence of other forms of liver disease (e.g., alcoholic liver
disease, hemochromatosis etc.); medical, social and psy-
chological implementation to compliance with the drug
regimen.
Patients were randomized to one of the two treatment
groups with the  following dosage regimen:
Ribavirin group: three 200 mg capsules twice daily
(1200 mg daily dose) and placebo group: three placebo cap-
sules twice daily. Study medication was to be administered
for 48 weeks.
Patient compliance with the study medication dosing
regimen was monitored by counting study medication cap-
sules at each study scheduled visit.
All concomitant medication used throughout the study
was on the appropriate Case Report Form (CRF) (generic
name/s, total daily dose/s, dose unit/s, duration of the treat-
ment and indication stated).
Patients were observed at regular intervals according
to the schedule. In total, there were 15 scheduled visits for
evaluation and laboratory tests.
Safety data were reported for all patients who received
at least one dose of study medication (total population).
Safety data included the following: adverse events  - any
symptom that occurred during the treatment period or be-
tween the patient’s last dose and final follow-up, was to be
recorded on the patient’s CRF. The investigator was to
evaluate each adverse event and record the severity of the
event and its relation to the study medication in the CRF,
and laboratory measurements.
The efficacy data were analyzed and reported for all
statistically evaluable patients.
Primary efficacy criteria: ALT response status  and
HCV RNA response status were defined as below:
≥ 50%  ALT/HCV RNA values − decrease ≥ 50% in
any stage of the study, as compared to the baseline
ALT/HCV RNA value;
< 50% ALT/HCV RNA values − decrease <50% in
any stage of the study, as compared to the baseline
ALT/HCV RNA value;
0% ALT/HCV RNA values − no change-or-increase in
any stage of the study, as compared to the baseline
ALT/HCV RNA value;
Primary efficacy analysis included: 1) comparison of
differences between the visits within the same group; 2)
comparison of differences between the study groups at the
same visit; 3) comparison ratio (values related to baseline)
between the study groups at the same visit, and 4) compari-
son of previously defined categorization data between the
study groups at the same visit.
Secondary efficacy variables were analyzed through
comparison differences between study groups within the
same visit. These comparisons were used for: 1) symptom
questionnaire parameters,  2) patient’s evaluation, and 3)
investigator’s evaluation.
Results
During the treatment period (0−48 week), the significant
changes of ALT values were detected in both study groups. In
the ribavirin group a decrease in ALT values was detected in
the period: 8−16 week, and 40−48 week. ALT values de-
crease was significantly lower in the ribavirin group.
During the post-treatment period (56−64 week), in the
ribavirin group, ALT values increased to the values ob-
tained in the screening period (8 weeks before the treat-
ment). Also, after 48-week treatment, there were no signifi-
cant differences in ALT values between the study groups.
ALT ratio comparison (n week/0 week) during the
treatment period, showed that ALT decrease was signifi-
cantly higher in the ribavirin group. In the post-treatment
period there were no differences.
In the ribavirin group, there were no significant statis-
tical differences in HCV RNA values between the sched-Страна 482 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 5
uled visits (week 0, 12, 24, 48 and 64). The same was for
the placebo group. Similarly, comparison of HCV RNA
values between the study groups showed no differences.
Knodell Score values did not significantly differ be-
tween the treatment groups, neither before, nor after the
treatment. Also, there were no significant differences in
values before the treatment and after the post-treatment pe-
riod.
Statistical analysis of the histopathological liver bi-
opsy categories showed no statistical differences except in
the marked portal inflammation category. Marked portal in-
flammation was lower after the treatment in ribavirin group.
Clinical symptom values (Symptom Questionnaire: fa-
tigue, anorexia, abdominal pain, patient condition, all
ranged 1−10), did not significantly differ between the
treatment groups.
Investigator’s evaluation showed statistically signifi-
cant differences in the benefit of ribavirin group.
Patient evaluation showed no differences between the
study groups.
Safety Results
Hematology parameters
Erythrocytes – during the study period there was sig-
nificant statistical decrease of values compared to the base-
line in the ribavirin group. In placebo group significant sta-
tistical decrease was detected in 12
th and 32
nd week of the
treatment period.
Comparing the values between the study groups, there
were significant statistical differences in weeks 4−32 (it was
lower in ribavirin group), but during the post-treatment pe-
riod (weeks 56−64), these values were lower in the placebo
group.
Leukocytes − in ribavirin group, values were higher than
baseline during week 2−20, but in the week 48 (the end of the
treatment period), values were lower than the baseline.
Placebo group showed no differences during the study
period.
Neutrophils – in week 2, and in week 8−48, neutro-
phils were higher than the baseline in ribavirin group; pla-
cebo group showed no statistical differences.
Basophilic − there were no differences, either between
the groups, or comparing the treatment weeks.
Lymphocytes − in ribavirin group values were signifi-
cantly lower in week 2 and during the period of week 8−48.
Placebo group showed no differences in any period of the
study.
Monocytes − lower values were during 40−48 week in
ribavirin group, while in placebo group there were no sta-
tistical differences.
Reticulocytes − in ribavirin group higher values were
detected during the period of 2−48 week of the treatment.
Placebo group showed no differences in any period of the
study.
Partial prothrombin time and prothrombin time − val-
ues for both parameters were significantly lower in ribavirin
group at the end of study (week 64). In placebo group there
were no differences.
Hemoglobin  − in ribavirin group  hemoglobin value
showed decreasing tendency (during: week 2−40). Values
ranged from 120 mg/100 ml to 130 mg/100 ml. At the end of
the treatment (week 40−48) values increased to 137 mg/100
ml. During the post-treatment period (week 56−64), values
reversed to pretreatment level, with no significance, compared
to the baseline. In placebo group hemoglobin values were
significantly lower during the treatment period, compared to
the baseline, especially during 12−16 week. Till the end of the
study values reversed to the baseline. During the treatment pe-
riod, hemoglobin values decrease was significantly higher in
ribavirin group, than in the placebo group.
Hematocrit − in ribavirin group values were signifi-
cantly lower in the treatment period (2−48 week), compared
to the baseline. In placebo group values were lower in week
4 and in the period of week 16−40. Comparison of ribavirin
and placebo hematocrit value decrease showed that it was
higher in ribavirin group.
All values in both groups reversed to thebaseline dur-
ing the post-treatment period (week 56−64).
Platelets  − ribavirin platelet values were statistically
higher during the treatment period (week 2−20, and week
32−48), and in week 64 (post-treatment period).  In placebo
group there were no differences in platelets values.
Clinical chemistry parameters
CD4, CD8, CD4/CD8, Alkaline phosphatase - values did
not differ during the study period.
AST − compared to the baseline, ribavirin group val-
ues were significantly lower during weeks 2 - 48; in placebo
group these values were lower during weeks 8−64.
During the treatment period, significantly lower values
occured in the ribavirin group.
Direct bilirubin, total bilirubin, blood urea nitrogen,
creatinine − showed no differences neither between treat-
ment weeks, nor between study groups.
Uric acid − ribavirin values were significantly higher
comparing the baseline during the treatment period − week
2−48, and in the post-treatment period, week 56. Placebo
group showed no differences.
Other safety evaluations included liver enlargement,
spleen enlargement, presence of icterus, Anti HCV − Anti C
1000, HBsAg. These values showed no differences, both
compared to the baseline, and to the study groups.
Discussion
Ribavirin is a synthetic purine nucleoside with demon-
strated antiviral activity against DNA and RNA viruses.
Previous clinical studies in patients with hepatitis C virus
suggested that ribavirin was an effective treatment, as dem-
onstrated by significant decreases in ALT activity and the
decrease in HCV RNA titer. This study was designed to
evaluate the effectiveness of a 48-week-course of ribavirin
therapy in patients with chronic active hepatitis C.Број 5 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Страна 483
Ribavirin was significantly more effective than placebo
in reducing ALT levels. Ribavirin patients showed noticeable
ALT reductions during the treatment period, (week 2−48).
During the post-treatment period, ALT values increased,
nearing the baseline ones. Placebo patients had no significant
ALT reductions observed during the treatment period. Also,
there was no increase in values in the post-treatment period.
HCV RNA values did not differ significantly between
the medications given (ribavirin vs. placebo) throughout the
whole study period.
Histopathologic examination of liver biopsy samples
was performed at the baseline, and once again between weeks
48 and 56.  Analysis was performed according to the Knodell
score system including: portal inflammation (mild, moderate,
marked); periportal activity and necrosis (mild piecemeal ne-
crosis, moderate, marked, moderate with bridging necrosis,
marked with bridging necrosis); lobular necrosis (mild, mod-
erate, marked) and fibrosis (mild fibrous portal expansion,
moderate with incomplete fibrosis septs, cirrhosis).
The proportion of ribavirin patients after the treat-
ment was significantly smaller (p<0.05) in the marked
portal inflammation category than in the categories of
mild and moderate portal inflammations. It suggested the
hypothesis that ribavirin exerted beneficial effect on por-
tal inflammation.
Conclusion
In this study ribavirin (1200 mg/day) was more ef-
fective than the placebo in reducing ALT levels during the
48-week treatment period in patients with chronic active
hepatitis C. There were no differences between the groups
in the post-treatment period. There was no difference be-
tween the groups in response based on HCV RNA titers.
Regarding the liver biopsy results, more ribavirin than
placebo patients showed improvement concerning portal
inflammation, but Knodell score values (before and after
treatment) did not significantly differ in any treatment
group. There were no statistical differences concerning
the adverse events. Analysis of laboratory data demon-
strated that ribavirin therapy was associated with a mild to
moderate reversible anemia.
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PROCENA EFIKASNOSTI I PODNOŠLJIVOSTI RIBAVIRINA KOD
BOLESNIKA SA HRONIČNOM INFEKCIJOM HEPATITIS C VIRUSOM
Uvod. Izveštaji hepatologa ukazuju da se antitela kod hroničnog hepatitisa C
(anti-HCV antitela) mogu detektovati u 71−84% slučajeva obolelih od post-
transfuzijskog hepatitisa i kod 50% slučajeva sa sporadičnim non-A non-B he-
patitisom. Anti-HCV antitela detektovana su kod 0,05−1% dobrovoljnih davala-
ca krvi, koji su imali normalan nivo alanintransaminaze (ALT) i negativan re-
zultat testiranja na anti-HBs. Prisustvo anti-HCV antitela je nađeno kod 67%Страна 484 ВОЈНОСАНИТЕТСКИ ПРЕГЛЕД Број 5
bolesnika, koji su u ličnoj anamnezi imali podatak o intravenskoj zloupotrebi
lekova ili podatak o autoimunskom hepatitisu, kao i kod 10−30% bolesnika sa
hepatocelularnim karcinomom. Ovo ukazuje na to da je virus hepatitisa C gla-
vni uzročnik akutnog i hroničnog hepatitisa širom sveta. Metode. Sprovedena
je multicentarska, internacionalna, duplo-slepa, randomizovana, placebom
kontrolisana studija. Posle osam nedelja praćenja, bolesnici su za vreme 48-
nedeljnog perioda terapije, randomizovano primali ribavirin 1200 mg dnevno ili
placebo. Kontrole su sprovođene u toku 16 nedelja postterapijskog perioda. U
ovu studiju je bilo uključeno 80 ambulantnih bolesnika, oba pola, kod kojih je
bila prisutna blaga do umerena hronična aktivna infekcija izazvana virusom
hepatitisa C. Rezultati. Za vreme terapijskog perioda, vrednosti ALT bile su
značajno smanjene u grupi bolesnika koji su primali ribavirin. Između ispitiva-
nih grupa (na terapiji ribavirinom i na placebu), nije postojala statistički značaj-
na razlika HCV RNK vrednosti. U grupi bolesnika koji su primali ribavirin, posle
prekida terapije, zabeležena je značajno niža portna inflamacija. Laboratorijska
analiza pokazala je da se u toku primene terapije ribavarinom javlja blaga do
umerena anemija reverzibilnog tipa. Procena istraživača o uticaju terapije na
opšte stanje bolesnika značajno se razlikovala u korist grupe pod terapijom ri-
bavirinom. Zaključak. Ova studija je pokazala da je u tretmanu hroničnog akti-
vnog hepatitisa C, za vreme primene terapije, ribavirin bio efikasniji od placeba
u snižavanju vrednosti ALT.
Kl juč ne reč i :  hepatitis C, hronični; ribavirin; alanin
aminotransferaza; krvna slika; hematokrit;
hepacivirus.